Brief Summary
This trial is for patients with primary mediastinal B-cell lymphomacancers of the lymphatic system (PMBL) and is evaluating if combining pembrolizumab with R-CHOP (Rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) will improve patient outcomes.
Intervention/Treatment
- Drug: Rituximab
- Drug: Pembrolizumab
- Drug: Cyclophosphamide
- Drug: Doxorubicin
- Drug: Vincristine
- Drug: Prednisolone
Inclusion Criteria
- Subjects aged equal to greater than 18 years at time of enrolment.
- Able to give informed consenta process in which a patient receives detailed information about a procedure or treatment, including its potential risks, benefits, and alternatives. The patient then has the opportunity to understand the information and voluntarily agree to the procedure or treatment..
- Clinical and histological diagnosisthe process of identifying a disease based on signs and symptoms, patient history and medical test results of PMBL, according to the current World Health Organization classification.
- No previous treatment for lymphoma including chemotherapya cancer treatment that uses drugs to kill or slow the growth of cancer cells, while minimising damage to healthy cells, radiotherapy or other investigational drug.
- Eastern Collaborative Oncologythe study, diagnosis and treatment of cancer Group performance status 0-<=1.
- Plateletssmall disc-shaped blood cells that clump together to form clots to stop bleeding >= 100×109/l; neutrophilsa type of white blood cell that act as a first responder to infections in the body >= 1.0×109/l at the time of study entry.
- Creatinine clearance >=30ml/min (calculated according to MRDR or Cockcroft Gault equation).
- Total bilirubin less than or equal to 1.5 × ULN, AST and ALT less or equal to 2..5 x ULN.
- LVEF greater or equal to 45%.